Conference Coverage

Hormonal contraception boosts breast cancer risk


 

EXPERT ANALYSIS FROM SDEF HAWAII DERMATOLOGY SEMINAR

Dr. Eichenfield pointed out that among Danish patients who used an oral contraceptive for less than 5 years, the excess risk of breast cancer went away within a year of stopping the medication. If patients used hormonal contraception for more than 5 years, the excess breast cancer risk lasted for 5 years after stopping.

He noted that the antiandrogen spironolactone, widely used off-label to treat adult female acne, has been shown to be free of any increased breast cancer risk.

He reported serving as a consultant to and/or recipient of research grants from more than a dozen pharmaceutical companies.

SDEF/Global Academy for Medical Education and this news organization are owned by the same parent company..

Pages

Recommended Reading

Women with adult acne need more treatment options and support
MDedge Family Medicine
Acne severity shows negative impact on women’s self esteem
MDedge Family Medicine
Acne evaluations using photos with digital tool comparable to in-person exams
MDedge Family Medicine
Topical retinoid plus benzoyl peroxide beats antibiotics for inflammatory acne
MDedge Family Medicine
Women with acne more likely to have hyperkeratinization, study finds
MDedge Family Medicine
VIDEO: What to monitor during isotretinoin treatment
MDedge Family Medicine
Acne is linked to higher chances of major depression
MDedge Family Medicine
Review finds some evidence of efficacy for nonpharmacological acne therapies
MDedge Family Medicine
Cost, coverage concerns cited as barriers to acne medication adherence
MDedge Family Medicine
Treating female-to-male transgender adolescents with acne presents unique concerns with depression
MDedge Family Medicine